Dubai hosts the 6th edition of the Middle East, Africa and Russia Hematology Summit MASH
This year's Hematology Summit, in its sixth version, focused more on clinical experience, devoting a full day of its program to workshops for hematologists and clinical pharmacists to share their experiences in managing challenging cases. Additionally, specialized workshops on AI role in healthcare and precision medicine, particularly in hematological diseases, were led by an international expert in artificial intelligence.
Dr. Ayman Al-Hijazi, Consultant Hematologist, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia, commended the holding of the 6th Hematology Summit and the attendance of that elite group of consultants and hematology experts. The conference showcased the latest diagnostic methods and various advanced treatments in hematology oncology, including AML, CLL, lymphoma, and others. Dr. Ayman also praised the valuable lectures included in the conference, which showcased advancements in the treatment of recurrent or refractory multiple myeloma, as well as revolutionary advances in cancer research and the transformative use of artificial intelligence in diagnosis and personalized treatment strategies.
Dr. Abdulwahab Al-Babtain, Consultant Hematologist and Cellular Therapist at King Faisal Specialist Hospital and Research Center in Riyadh, welcomed everyone who participated in the success of this summit. He added that the summit addressed new developments in the treatment of benign and malignant blood diseases and tumors. The conference also featured extensive scientific and medical content, including scientific papers presented and workshops, including workshops on lymphoma and leukemia, management of complications resulting from blood cancers, treatment sequencing for chronic lymphocytic leukemia, and the importance of detecting genetic mutations in acute myeloid leukemia. Dr. Abdulwahab explained that there has been significant development in medications for treating blood diseases, which will significantly contribute to controlling the disease and alleviating patients' suffering. This is based on the latest clinical studies and how to choose the appropriate treatment for each individual case, in accordance with the latest scientific recommendations in this field.
Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, emphasized that such scientific summits align with AbbVie's mission and its focus on medical education, training, scientific research, and providing distinguished medical care, in line with the Kingdom's Vision 2030. This was evident in this version of the conference, which showcased the role of AI in accurate disease diagnosis, discussed new treatments for unmet clinical needs, and highlighted the importance of early detection and optimal management of the disease, with the goal of improving patients' lives.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Syyaha
02-07-2025
- Syyaha
Dubai hosts the 6th edition of the Middle East, Africa and Russia Hematology Summit MASH
The Hematology Medical Conference, sponsored by AbbVie, the global research and development company in the field of biopharmaceuticals, kicked off for the sixth consecutive year at the Intercontinental Festival City, Dubai, UAE. This summit represents a major regional collaboration for medical affairs in the field of hematology, with a robust history of collaboration in five previous successful versions. The summit featured a group of elite national and international experts and more than 25 speakers from across the Middle East, Africa, and Russia, as well as international speakers, including a hematologist from Canada and an AI expert from healthcare practitioners from the United States. This year's Hematology Summit, in its sixth version, focused more on clinical experience, devoting a full day of its program to workshops for hematologists and clinical pharmacists to share their experiences in managing challenging cases. Additionally, specialized workshops on AI role in healthcare and precision medicine, particularly in hematological diseases, were led by an international expert in artificial intelligence. Dr. Ayman Al-Hijazi, Consultant Hematologist, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia, commended the holding of the 6th Hematology Summit and the attendance of that elite group of consultants and hematology experts. The conference showcased the latest diagnostic methods and various advanced treatments in hematology oncology, including AML, CLL, lymphoma, and others. Dr. Ayman also praised the valuable lectures included in the conference, which showcased advancements in the treatment of recurrent or refractory multiple myeloma, as well as revolutionary advances in cancer research and the transformative use of artificial intelligence in diagnosis and personalized treatment strategies. Dr. Abdulwahab Al-Babtain, Consultant Hematologist and Cellular Therapist at King Faisal Specialist Hospital and Research Center in Riyadh, welcomed everyone who participated in the success of this summit. He added that the summit addressed new developments in the treatment of benign and malignant blood diseases and tumors. The conference also featured extensive scientific and medical content, including scientific papers presented and workshops, including workshops on lymphoma and leukemia, management of complications resulting from blood cancers, treatment sequencing for chronic lymphocytic leukemia, and the importance of detecting genetic mutations in acute myeloid leukemia. Dr. Abdulwahab explained that there has been significant development in medications for treating blood diseases, which will significantly contribute to controlling the disease and alleviating patients' suffering. This is based on the latest clinical studies and how to choose the appropriate treatment for each individual case, in accordance with the latest scientific recommendations in this field. Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, emphasized that such scientific summits align with AbbVie's mission and its focus on medical education, training, scientific research, and providing distinguished medical care, in line with the Kingdom's Vision 2030. This was evident in this version of the conference, which showcased the role of AI in accurate disease diagnosis, discussed new treatments for unmet clinical needs, and highlighted the importance of early detection and optimal management of the disease, with the goal of improving patients' lives.
Syyaha
15-06-2025
- Syyaha
The 5th International Neuroscience Summit for the Middle East, Africa and Russia (MEANS) is being held in Dubai.
The International Neurology Conference for the Middle East, Africa and Russia kicked off in Dubai, in cooperation with AbbVie, the global biopharmaceutical research and development company, with the participation of an elite group of international and national speakers and in the presence of several consultants, specialist physicians, researchers, professors and neurology experts from Gulf countries, Saudi Arabia, Egypt and Russia, in addition to several international, regional and local medical associations. The conference included several scientific lectures that discuss the latest research and treatment methods for many neurological diseases such as Parkinson's disease, migraine and post-stroke spasticity. Dr. Abdulrazzaq Al-Bilali, Headache Specialist and Head of the Saudi Headache Chapter, Saudi Neurology Society, commended the continuous efforts of the organizers of this major conference and its success for the fifth consecutive year. Dr. Abdulrazzaq emphasized that scientific research is the cornerstone of progress in the field of neurology. He explained that headache is a health problem that significantly impacts people's lives and daily activities, and that significant developments have occurred in diagnostic methods and disease management. He emphasized that the future of patient care lies in innovation and evidence-based knowledge. For his part, Dr. Suhail Al Rukun, consultant neurology, President of Emirates neurology Society in the United Arab Emirates, praised the large turnout at the conference, which included valuable medical discussions, workshops, and a review of the latest recommendations from clinical trials and research in this sector, in addition to presenting the best methods used in the management of patients with neurological diseases. Dr. Suhail added that this prominent scientific event is a good opportunity to exchange experiences and keep up with the latest developments in the neurology field. Organizing this summit for the fifth consecutive year embodies the ongoing commitment to enhancing medical knowledge and achieving the best treatment outcomes for patients. These initiatives help improve the quality of healthcare and open new horizons for improving patients' lives. Mohammad Aboubakr, Vice President and General Manager of AbbVie's Middle East, Africa & Russia region, commended the launch of the fifth Neurology Summit, which highlighted the latest emerging scientific and medical developments. He emphasized that organizing the summit reflects AbbVie's commitment to enhancing scientific training and research programs and providing a high level of medical care to serve society members by providing what helps improve their quality of life. The company seeks to help make a real difference in patients' lives, as well as its commitment to raising awareness and health education for patients, and on the other hand, its focus on the fields of education, training and scientific research
Syyaha
07-05-2025
- Syyaha
MOU between the Saudi Society of Dermatology and Dermatologic Surgery (SSDDS), AbbVie and Al Nahdi Medical Company
The Saudi Society of Dermatology and Dermatologic Surgery SSDDS, the leading professional body for dermatologists in Saudi Arabia, signed a Memorandum of Understanding with AbbVie Saudi Arabia, the global biopharmaceutical research and development company, and Al Nahdi Medical Company, the largest retail pharmacy chain in the Middle East and Africa. The MOU aims to collaborate on enhancing public health services, awareness programs, and advancing disease management through innovative healthcare solutions. The MOU also aims to strengthen the role of the Saudi Society of Dermatology through partnerships between the private and public entities to drive innovative healthcare solutions in line with Saudi Vision 2030. Dr. Abdullah Al-Aqeel, President of SSDDS, pointed out that the MOU primarily aims to collaborate on patient education and awareness campaigns, particularly on psoriasis and atopic dermatitis, their symptoms, and treatment options. It also aims to provide patients with access to accurate and culturally relevant educational materials. It also aims to train and support healthcare professionals by conducting training sessions and workshops in collaboration with SSDDS to hone the skills of dermatologists and healthcare providers on the latest developments in the treatment of atopic dermatitis and psoriasis. Dr. Maysa Ashmawy, Head of Dermatology at Saudi Ministry of Health, and a member of the Board of the Saudi Society of Dermatology and Dermatologic Surgery, emphasized the importance of such partnerships, which aim to improve healthcare services, and to contribute to research in collaboration with SSDDS, in addition to sharing insights with healthcare providers in line with national public health objectives. Dr. Afaf Al-Sheikh, Consultant and Head of the Dermatology Department at King Abdulaziz Medical City and the National Guard, commended the signing of the MOU, which aims to establish a collaborative framework to advance the management of psoriasis and atopic dermatitis in Saudi Arabia. She also emphasized the need to raise awareness of these cases, promote early diagnosis and treatment, and improve healthcare access and quality, in alignment with Saudi Vision 2030. She added that SSDDS as always, is fulfilling its developmental and training role by organizing professional training sessions for dermatologists and healthcare providers, facilitating research initiatives, and sharing insights on disease management trends. For his part, Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, emphasized AbbVie's efforts to collaborate with health authorities in the Kingdom to provide healthcare and awareness services, provide training resources, support healthcare professional education initiatives, and collaborate on patient awareness and outreach programs. He added, AbbVie's mission is to discover and deliver innovative medicines and solutions that solve today's serious health issues and address future medical challenges. The company also strives to make a remarkable impact on people's lives in several key therapeutic areas, including immunology, oncology and neuroscience.
